Has anyone elected to receive triple drug therapy and delay their ASCT? Seems like there is…
Has anyone elected to receive triple drug therapy and delay their ASCT? Seems like there is increasing evidence that this may be a good approach.
The Evolving Role of Transplant in Multiple Myeloma in 2019 and Beyond - Dana-Farber Cancer Institute | Boston, MA
The use of autologous stem cell transplant (ASCT) for selected patients along with the introduction of novel agents has, over the past two decades, markedly improved the median overall survival (OS) of patients to around 7 to 10 years in younger patients.